

100 pozicija

# Nobori


*Drug Eluting Stent with Biodegradable Polymer*

The biodegradable choice  
for patient safety

 TERUMO®

# Biolimus A9\*

a new limus drug designed for stent application provides efficacy




+

- Powerful anti-proliferative and anti-inflammatory properties to reduce neo-intimal proliferation
- Precise release kinetics with an initial burst and sustained elution through polymer degradation for long term efficacy
- Biolimus high lipophilicity facilitates diffusion into the vessel wall to provide an efficient local effect

In stent late loss  $0.11 \text{ mm} \pm 0.30 \text{ mm}^{(1)}$

# Biodegradable polymer PLA

on abluminal surface preserves endothelial function



+

- No drug on luminal surface enhances endothelialization
- Fully biodegradable PLA polymer eliminates chronic sensitivity and ensures complete drug release

Proven long-term safety


\* TM by Biosensors

1 NORORI 1 phase 2 (Chevalier B. *Circ Cardiovasc Interv* 2009;2:188-195)

# Clinical results

## NOBORI 1


9 month angiographic follow-up



NOBORI 1 phase 2 (Chevalier B. Circ Cardiovasc Interv 2009;2:188-195)

## NOBORI JAPAN

8 month angiographic follow-up




Kadota K. CCI 2011

Nobori® demonstrates higher efficacy compared to Taxus Drug Eluting Stent

## NOBORI 1


Stent Thrombosis at 5 years - both cohorts\*



Stent thrombosis = Definite and Probable according to ARC definition  
 \* Pooled data from NOBORI 1, phase 1 and phase 2 Chevalier B. - EuroPCR 2010  
 \*\* Data on file Terumo Europe N.V.


## NOBORI 2 Study

Composite Endpoints at 3 years



TLF = Cardiac death, MI (TV related), TLR  
 MACE = Cardiac death, any MI, TVR  
 Danzi GB, EuroPCR 2012

Nobori® has proven safe across the board for challenging lesions and high-risk patient subgroups




# Design supported by an extensive clinical program (>20.000 patients)

Foundation		
<b>NOBORI PK</b>	Single arm – FU 5 years	N=20
<b>NOBORI 1 Phase 1</b>	Randomized – Taxus – FU 5 years	N=120
<b>NOBORI 1 Phase 2</b>	Randomized – Taxus – FU 5 years	N=243
<b>NOBORI CORE</b>	Comparative Cypher – FU 5 years	N=107
<b>NOBORI Japan</b>	Randomized Cypher – FU 3 years	N=323

Registries		
<b>NOBORI 2</b>	Single Arm - FU 3 years	N=3067
<b>e-NOBORI</b>	Single Arm - Enrolling	N=8000
<b>IRIS - NOBORI</b>	Single Arm - Enrolling	N=1000

Real Life Randomized		
<b>COMPARE 2</b>	Nobori vs Xience V – PCR 2012	N=2700
<b>BASKET PROVE 2</b>	Nobori vs Xience vs BMS – Enrolling	N=2400
<b>SORT-OUT V</b>	Nobori vs Cypher – PCR 2012	N=2400
<b>ISAR Test 6</b>	Nobori vs Xience vs ISAR GE	N=2010
<b>SECURITY</b>	6 VS 12 months DAT	N=4000


Taxus is a trademark of Boston Scientific Corporation.  
 Xience is a trademark of Abbott Laboratories.  
 Cypher is a trademark of J&J / Cordis Corporation.  
 Bolimus A9 is a trademark of Biosensors.




# Open cell design stent on a low compliant balloon for superior deliverability

+

- Low compliant balloon ensures optimal stent expansion
- Open cell for convenient side branch access
- Innovative Ryujin™ shaft offers outstanding crossability



Before procedure



After procedure

